{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:53:12Z","timestamp":1768971192379,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1097\/fpc.0000000000000361","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T22:23:48Z","timestamp":1543271028000},"page":"18-22","source":"Crossref","is-referenced-by-count":13,"title":["Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy"],"prefix":"10.1097","volume":"29","author":[{"given":"Kimberly S.","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria M.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley M.","family":"Stansberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Kannegolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marelize","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjani N.","family":"Moorthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Eadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210214","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R2-3-20210214","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte: an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R3-3-20210214","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/pgs.13.202","article-title":"Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension","volume":"15","author":"Spinasse","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R4-3-20210214","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.2008.139","article-title":"beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension","volume":"84","author":"Pacanowski","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R5-3-20210214","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/jhh.2015.121","article-title":"The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study","volume":"30","author":"Do","year":"2016","journal-title":"J Hum Hypertens"},{"key":"R6-3-20210214","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCGENETICS.112.964080","article-title":"Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study","volume":"5","author":"Gong","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"R7-3-20210214","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/HYPERTENSIONAHA.112.198721","article-title":"G protein receptor kinase 4 polymorphisms: \u03b2-blocker pharmacogenetics and treatment-related outcomes in hypertension","volume":"60","author":"Vandell","year":"2012","journal-title":"Hypertension"},{"key":"R8-3-20210214","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.ki.5001590","article-title":"24-h ambulatory blood pressure is linked to chromosome 18q21\u201322 and genetic variation of NEDD4L associates with cross-sectional and longitudinal blood pressure in Swedes","volume":"70","author":"Fava","year":"2006","journal-title":"Kidney Int"},{"key":"R9-3-20210214","doi-asserted-by":"crossref","first-page":"001521","DOI":"10.1161\/JAHA.114.001521","article-title":"Pharmacogenomics of hypertension: a genome\u2010wide, placebo\u2010controlled cross\u2010over study, using four classes of antihypertensive drugs","volume":"4","author":"Hiltunen","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R10-3-20210214","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/pgs-2016-0204","article-title":"Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses","volume":"18","author":"Rimpel\u00e4","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R11-3-20210214","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/HYPERTENSIONAHA.107.104273","article-title":"Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic","volume":"52","author":"Turner","year":"2008","journal-title":"Hypertension"},{"key":"R12-3-20210214","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/23808993.2018.1420419","article-title":"Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment","volume":"3","author":"Eadon","year":"2018","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"R13-3-20210214","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ackd.2016.02.003","article-title":"A physiologic approach to the pharmacogenomics of hypertension","volume":"23","author":"Eadon","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"R14-3-20210214","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R15-3-20210214","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R18-3-20210214","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R19-3-20210214","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ng.568","article-title":"New loci associated with kidney function and chronic kidney disease","volume":"42","author":"K\u00f6ttgen","year":"2010","journal-title":"Nat Genet"},{"key":"R20-3-20210214","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.2015101152","article-title":"Genome-wide association of CKD progression: the chronic renal insufficiency cohort study","volume":"28","author":"Parsa","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R21-3-20210214","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N Engl J Med"},{"key":"R22-3-20210214","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/HJH.0000000000001527","article-title":"The value of uromodulin as a new serum marker to predict decline in renal function","volume":"36","author":"Leiherer","year":"2018","journal-title":"J Hypertens"},{"key":"R23-3-20210214","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/j.ajkd.2018.02.351","article-title":"Genetic testing in clinical settings","volume":"72","author":"Franceschini","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R24-3-20210214","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jmoldx.2015.11.003","article-title":"Analytical validation of a personalized medicine APOL1 genotyping assay for nondiabetic chronic kidney disease risk assessment","volume":"18","author":"Zhang","year":"2016","journal-title":"J Mol Diagn"},{"key":"R25-3-20210214","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2353\/jmoldx.2010.100090","article-title":"Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and association for molecular pathology collaborative project","volume":"12","author":"Pratt","year":"2010","journal-title":"J Mol Diagn"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:24:35Z","timestamp":1620951875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201901000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000361","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}